Social Media Suggests an MS Dogfight Between Biogen, Inc. and Novartis AG (NVS)
5/24/2013 8:28:41 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Over the past month, surveying the track record for the newly launched Tecfidera multiple sclerosis pill has become a closely watched exercise on Wall Street. Each week, analysts pore over prescription data to gauge the extent to which the drug, which is sold by Biogen Idec, is capturing market share and how many billions of dollars in sales may be generated this year (back story).
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by